Healthcare Finance News December 7, 2022
Jeff Lagasse

The company believes the equivalent therapies will lower healthcare costs while providing more choice and flexibility.

Pharmacy benefit manager Express Scripts, part of Cigna’s Evernorth subsidiary, will be adding Humira biosimilars to its formulary in 2023 as preferred products, which will be available to patients with inflammatory conditions.

A number of biosimilar therapies clinically equivalent to Humira are expected to become available next year, all approved by the Food and Drug Administration and with no clinically meaningful differences in safety and efficacy, according to a statement from Evernorth. 

The company expects these equivalent therapies will help to drive down healthcare costs and give patients and providers more choice and flexibility.

“Lack of competition allows sky-high prescription drug prices,” said Harold...

Today's Sponsors


Today's Sponsor

Health Edge

Topics: Biotechnology, Pharma / Biotech
J&J's pharma group quietly works through global overhaul, with layoffs expected to reach multiple countries
Inflation Reduction Act Could Cut Medicare Drug Spending by 5%, Study Suggests
Pfizer and Ada Health Inc. To Launch Nationwide Online COVID-19 Care Journey
Chutes & Ladders—Ginkgo BioWorks CEO to lead federal biotech commission
Smoothing Medicare Part D Out-Of-Pocket Costs Under The Inflation Reduction Act

Share This Article